CONTEDUCA, VINCENZA
CONTEDUCA, VINCENZA
Dipartimento di Scienze Mediche e Chirurgiche
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide
2015-01-01 De Giorgi, U.; Caroli, P.; Scarpi, E.; Conteduca, V.; Burgio, S. L.; Menna, C.; Moretti, A.; Galassi, R.; Rossi, L.; Amadori, D.; Paganelli, G.; Matteucci, F.
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma.
2019-01-01 Lolli, C; Altavilla, A; Conteduca, V; Farolfi, A; Casadei, C; Schepisi, G; Banna, Gl; De Giorgi, U.
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer
2019-01-01 Caffo, O; Facchini, G; Biasco, E; Ferraù, F; Morelli, F; Donini, M; Buttigliero, C; Calvani, N; Guida, A; Chiuri, Ve; Basso, U; Mucciarini, C; Conteduca, V; Rossetti, S; Veccia, A; Maines, F; Kinspergher, S; De Giorgi, U.
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.
2020-01-01 Schmid, S; Omlin, A; Higano, C; Sweeney, C; Martinez Chanza, N; Mehra, N; Kuppen, Mcp; Beltran, H; Conteduca, V; Vargas Pivato de Almeida, D; Cotait Maluf, F; Oh, Wk; Tsao, Ck; Sartor, O; Ledet, E; Di Lorenzo, G; Yip, Sm; Chi, Kn; Bianchini, D; De Giorgi, U; Hansen, Ar; Beer, Tm; Lavaud, P; Morales-Barrera, R; Tucci, M; Castro, E; Karalis, K; Bergman, Am; Le, Ml; Zürrer-Härdi, U; Pezaro, C; Suzuki, H; Zivi, A; Klingbiel, D; Schär, S; Gillessen, S.
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA.
2021-01-01 Conteduca, V; Brighi, N; Conteduca, D; Bleve, S; Gianni, C; Schepisi, G; Iaia, Ml; Gurioli, G; Lolli, C; De Giorgi, U.
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide.
2021-01-01 Del Re, M; Conteduca, V; Crucitta, S; Gurioli, G; Casadei, C; Restante, G; Schepisi, G; Lolli, C; Cucchiara, F; Danesi, R; De Giorgi, U.
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study
2017-01-01 Conteduca, V.; Wetterskog, D.; Sharabiani, M. T. A.; Grande, E.; Fernandez-Perez, M. P.; Jayaram, A.; Salvi, S.; Castellano, D.; Romanel, A.; Lolli, C.; Casadio, V.; Gurioli, G.; Amadori, D.; Font, A.; Vazquez-Estevez, S.; Gonzalez del Alba, A.; Mellado, B.; Fernandez-Calvo, O.; Mendez-Vidal, M. J.; Climent, M. A.; Duran, I.; Gallardo, E.; Rodriguez, A.; Santander, C.; Saez, M. I.; Puente, J.; Gasi Tandefelt, D.; Wingate, A.; Dearnaley, D.; Demichelis, F.; De Giorgi, U.; Gonzalez-Billalabeitia, E.; Attard, G.; Alonso, T.; Tudela, J.; Martinez, A.
Androgen receptor signaling pathways as a target for breast cancer treatment
2016-01-01 Pietri, E.; Conteduca, V.; Andreis, D.; Massa, I.; Melegari, E.; Sarti, S.; Cecconetto, L.; Schirone, A.; Bravaccini, S.; Serra, P.; Fedeli, A.; Maltoni, R.; Amadori, D.; De Giorgi, U.; Rocca, A.
Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer?
2024-01-01 Garofoli, Marianna; Maiorano, Brigida Anna; Bruno, Giuseppina; Giordano, Guido; Di Tullio, Piergiorgio; Maselli, Felicia Maria; Landriscina, Matteo; Conteduca, Vincenza
Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy.
2021-01-01 Conteduca, V; Medri, M; Mazzoni, L; De Giorgi, U; Stanganelli, I.
AR copy number and AR signaling-directed therapies in castration-resistant prostate cancer
2018-01-01 Salvi, S.; Conteduca, V.; Lolli, C.; Testoni, S.; Casadio, V.; Zaccheroni, A.; Rossi, L.; Burgio, S. L.; Menna, C.; Schepisi, G.; De Giorgi, U.
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation
2022-01-01 Sanguedolce, Francesca; Zanelli, Magda; Palicelli, Andrea; Ascani, Stefano; Zizzo, Maurizio; Cocco, Giorgia; Björnebo, Lars; Lantz, Anna; Landriscina, Matteo; Conteduca, Vincenza; Falagario, Ugo Giovanni; Cormio, Luigi; Carrieri, Giuseppe
Association among metabolic syndrome, inflammation, and survival in prostate cancer
2018-01-01 Conteduca, V; Caffo, O; Galli, L; Maugeri, A; Scarpi, E; Maines, F; Chiuri, Ve; Lolli, C; Kinspergher, S; Schepisi, G; Santoni, M; Santini, D; Fratino, L; Burgio, Sl; Salvi, S; Menna, C; De Giorgi, U.
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer
2016-01-01 Conteduca, V.; Crabb, S. J.; Scarpi, E.; Hanna, C.; Maines, F.; Joyce, H.; Fabbri, P.; Derosa, L.; Massari, F.; Lolli, C.; Zarif, S.; Jones, R. J.; Caffo, O.; Elliott, T.; De Giorgi, U.
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study
2016-01-01 D'Aniello, C.; Vitale, M. G.; Farnesi, A.; Calvetti, L.; Laterza, M. M.; Cavaliere, C.; Pepa, C. D.; Conteduca, V.; Crispo, A.; De Vita, F.; Grillone, F.; Ricevuto, E.; De Tursi, M.; De Vivo, R.; Di Napoli, M.; Cecere, S. C.; Iovane, G.; Amore, A.; Piscitelli, R.; Quarto, G.; Pisconti, S.; Ciliberto, G.; Maiolino, P.; Muto, P.; Perdona, S.; Berretta, M.; Naglieri, E.; Galli, L.; Carteni, G.; Giorgi, U. D.; Pignata, S.; Facchini, G.; Rossetti, S.
B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia
2013-01-01 Sansonno, D.; Russi, S.; Conteduca, V.; Sansonno, L.
Barrett's esophagus and esophageal cancer: An overview
2012-01-01 Conteduca, V.; Sansonno, D.; Ingravallo, G.; Marangi, S.; Russi, S.; Lauletta, G.; Dammacco, F.
Barrett's esophagus and esophageal cancer: An overview
2012-01-01 Conteduca, V.; Sansonno, D.; Ingravallo, G.; Marangi, S.; Russi, S.; Lauletta, G.; Dammacco, F.
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
2022-01-01 Conteduca, Vincenza; Casadei, Chiara; Scarpi, Emanuela; Brighi, Nicole; Schepisi, Giuseppe; Lolli, Cristian; Gurioli, Giorgia; Toma, Ilaria; Poti, Giulia; Farolfi, Alberto; De Giorgi, Ugo
Biological Evolution of Castration-resistant Prostate Cancer
2019-01-01 Davies, A; Conteduca, V; Zoubeidi, A; Beltran, H.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide | 1-gen-2015 | De Giorgi, U.; Caroli, P.; Scarpi, E.; Conteduca, V.; Burgio, S. L.; Menna, C.; Moretti, A.; Galassi, R.; Rossi, L.; Amadori, D.; Paganelli, G.; Matteucci, F. | |
| A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. | 1-gen-2019 | Lolli, C; Altavilla, A; Conteduca, V; Farolfi, A; Casadei, C; Schepisi, G; Banna, Gl; De Giorgi, U. | |
| Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer | 1-gen-2019 | Caffo, O; Facchini, G; Biasco, E; Ferraù, F; Morelli, F; Donini, M; Buttigliero, C; Calvani, N; Guida, A; Chiuri, Ve; Basso, U; Mucciarini, C; Conteduca, V; Rossetti, S; Veccia, A; Maines, F; Kinspergher, S; De Giorgi, U. | |
| Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. | 1-gen-2020 | Schmid, S; Omlin, A; Higano, C; Sweeney, C; Martinez Chanza, N; Mehra, N; Kuppen, Mcp; Beltran, H; Conteduca, V; Vargas Pivato de Almeida, D; Cotait Maluf, F; Oh, Wk; Tsao, Ck; Sartor, O; Ledet, E; Di Lorenzo, G; Yip, Sm; Chi, Kn; Bianchini, D; De Giorgi, U; Hansen, Ar; Beer, Tm; Lavaud, P; Morales-Barrera, R; Tucci, M; Castro, E; Karalis, K; Bergman, Am; Le, Ml; Zürrer-Härdi, U; Pezaro, C; Suzuki, H; Zivi, A; Klingbiel, D; Schär, S; Gillessen, S. | |
| An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA. | 1-gen-2021 | Conteduca, V; Brighi, N; Conteduca, D; Bleve, S; Gianni, C; Schepisi, G; Iaia, Ml; Gurioli, G; Lolli, C; De Giorgi, U. | |
| Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. | 1-gen-2021 | Del Re, M; Conteduca, V; Crucitta, S; Gurioli, G; Casadei, C; Restante, G; Schepisi, G; Lolli, C; Cucchiara, F; Danesi, R; De Giorgi, U. | |
| Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study | 1-gen-2017 | Conteduca, V.; Wetterskog, D.; Sharabiani, M. T. A.; Grande, E.; Fernandez-Perez, M. P.; Jayaram, A.; Salvi, S.; Castellano, D.; Romanel, A.; Lolli, C.; Casadio, V.; Gurioli, G.; Amadori, D.; Font, A.; Vazquez-Estevez, S.; Gonzalez del Alba, A.; Mellado, B.; Fernandez-Calvo, O.; Mendez-Vidal, M. J.; Climent, M. A.; Duran, I.; Gallardo, E.; Rodriguez, A.; Santander, C.; Saez, M. I.; Puente, J.; Gasi Tandefelt, D.; Wingate, A.; Dearnaley, D.; Demichelis, F.; De Giorgi, U.; Gonzalez-Billalabeitia, E.; Attard, G.; Alonso, T.; Tudela, J.; Martinez, A. | |
| Androgen receptor signaling pathways as a target for breast cancer treatment | 1-gen-2016 | Pietri, E.; Conteduca, V.; Andreis, D.; Massa, I.; Melegari, E.; Sarti, S.; Cecconetto, L.; Schirone, A.; Bravaccini, S.; Serra, P.; Fedeli, A.; Maltoni, R.; Amadori, D.; De Giorgi, U.; Rocca, A. | |
| Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer? | 1-gen-2024 | Garofoli, Marianna; Maiorano, Brigida Anna; Bruno, Giuseppina; Giordano, Guido; Di Tullio, Piergiorgio; Maselli, Felicia Maria; Landriscina, Matteo; Conteduca, Vincenza | |
| Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy. | 1-gen-2021 | Conteduca, V; Medri, M; Mazzoni, L; De Giorgi, U; Stanganelli, I. | |
| AR copy number and AR signaling-directed therapies in castration-resistant prostate cancer | 1-gen-2018 | Salvi, S.; Conteduca, V.; Lolli, C.; Testoni, S.; Casadio, V.; Zaccheroni, A.; Rossi, L.; Burgio, S. L.; Menna, C.; Schepisi, G.; De Giorgi, U. | |
| Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation | 1-gen-2022 | Sanguedolce, Francesca; Zanelli, Magda; Palicelli, Andrea; Ascani, Stefano; Zizzo, Maurizio; Cocco, Giorgia; Björnebo, Lars; Lantz, Anna; Landriscina, Matteo; Conteduca, Vincenza; Falagario, Ugo Giovanni; Cormio, Luigi; Carrieri, Giuseppe | |
| Association among metabolic syndrome, inflammation, and survival in prostate cancer | 1-gen-2018 | Conteduca, V; Caffo, O; Galli, L; Maugeri, A; Scarpi, E; Maines, F; Chiuri, Ve; Lolli, C; Kinspergher, S; Schepisi, G; Santoni, M; Santini, D; Fratino, L; Burgio, Sl; Salvi, S; Menna, C; De Giorgi, U. | |
| Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer | 1-gen-2016 | Conteduca, V.; Crabb, S. J.; Scarpi, E.; Hanna, C.; Maines, F.; Joyce, H.; Fabbri, P.; Derosa, L.; Massari, F.; Lolli, C.; Zarif, S.; Jones, R. J.; Caffo, O.; Elliott, T.; De Giorgi, U. | |
| Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study | 1-gen-2016 | D'Aniello, C.; Vitale, M. G.; Farnesi, A.; Calvetti, L.; Laterza, M. M.; Cavaliere, C.; Pepa, C. D.; Conteduca, V.; Crispo, A.; De Vita, F.; Grillone, F.; Ricevuto, E.; De Tursi, M.; De Vivo, R.; Di Napoli, M.; Cecere, S. C.; Iovane, G.; Amore, A.; Piscitelli, R.; Quarto, G.; Pisconti, S.; Ciliberto, G.; Maiolino, P.; Muto, P.; Perdona, S.; Berretta, M.; Naglieri, E.; Galli, L.; Carteni, G.; Giorgi, U. D.; Pignata, S.; Facchini, G.; Rossetti, S. | |
| B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia | 1-gen-2013 | Sansonno, D.; Russi, S.; Conteduca, V.; Sansonno, L. | |
| Barrett's esophagus and esophageal cancer: An overview | 1-gen-2012 | Conteduca, V.; Sansonno, D.; Ingravallo, G.; Marangi, S.; Russi, S.; Lauletta, G.; Dammacco, F. | |
| Barrett's esophagus and esophageal cancer: An overview | 1-gen-2012 | Conteduca, V.; Sansonno, D.; Ingravallo, G.; Marangi, S.; Russi, S.; Lauletta, G.; Dammacco, F. | |
| Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide | 1-gen-2022 | Conteduca, Vincenza; Casadei, Chiara; Scarpi, Emanuela; Brighi, Nicole; Schepisi, Giuseppe; Lolli, Cristian; Gurioli, Giorgia; Toma, Ilaria; Poti, Giulia; Farolfi, Alberto; De Giorgi, Ugo | |
| Biological Evolution of Castration-resistant Prostate Cancer | 1-gen-2019 | Davies, A; Conteduca, V; Zoubeidi, A; Beltran, H. |